20:58 , Nov 11, 2016 |  BC Week In Review  |  Company News

HEC, TaiGen deal

TaiGen’s TaiGen BioPharmaceuticals Co. subsidiary and HEC’s YiChang HEC ChangJiang Pharmaceutical Co. Ltd. (HKSE:1558, Gongguan, China) will establish an unnamed newco in China to develop and commercialize antiviral agents to treat chronic HCV infection. HEC...
07:00 , Oct 31, 2016 |  BC Extra  |  Company News

TaiGen, HEC launch cross-strait newco for HCV combo

TaiGen Biopharmaceuticals Holdings Ltd. (TPex:4157) and the YiChang HEC ChangJiang Pharmaceutical Co. Ltd. (HKSE:1558) subsidiary of HEC Pharm Group (Dongguan, China) launched a newco that intends to develop HCV therapies for Greater China. The partners...
01:55 , May 20, 2015 |  BC Extra  |  Top Story

Achillion, Janssen partner to develop HCV combo

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) granted the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to develop and commercialize treatment regimens containing Achillion's HCV assets. Achillion's HCV pipeline includes ACH-3102, a pan-genotypic,...
04:39 , Jan 17, 2015 |  BC Extra  |  Company News

EC approves AbbVie's HCV regimen

The European Commission approved Exviera dasabuvir and Viekirax, a two direct-acting-antiviral (2-DAA) combination of ombitasvir and paritaprevir plus the booster Norvir ritonavir from AbbVie Inc. (NYSE:ABBV) to treat chronic HCV infection. The EC approved the...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Phage-assisted continuous evolution (PACE) to identify and predict drug-resistant protease mutations caused by protease inhibitors An in vitro...
02:24 , Nov 22, 2014 |  BC Extra  |  Company News

CHMP gives nod to AbbVie's HCV therapies

EMA's CHMP recommended approval of Exviera dasabuvir and Viekirax, which is a two direct-acting-antiviral (2-DAA) combination of ombitasvir and paritaprevir ( ABT-450) plus the booster Norvir ritonavir from AbbVie Inc. (NYSE:ABBV) to treat chronic HCV...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Clinical News

ABT-450 plus ritonavir/ombitasvir: Phase II data

The open-label, international Phase II CORAL-I trial in 34 non-cirrhotic, liver transplant patients with recurrent chronic HCV genotype 1 infection showed that AbbVie's all-oral 3D regimen -- comprising co-administration with once-daily 150 mg ABT-450 plus...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Clinical News

ABT-450 plus ritonavir/ombitasvir: Phase IIb data

Data from 91 evaluable non-cirrhotic patients with HCV genotype 4 infection in the open-label Phase IIb PEARL-I trial showed that an all-oral once-daily regimen comprising co-administration with 150 mg ABT-450 plus 100 mg ritonavir and...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Clinical News

ABT-450 plus ritonavir/ombitasvir: Phase II/III data

Data from 63 patients co-infected with HCV genotype 1 and HIV with or without compensated liver cirrhosis in part 1 of the 2-part, open-label, U.S. Phase II/III TURQUOISE-I trial showed that AbbVie's all-oral 3D regimen...
02:16 , Nov 12, 2014 |  BC Extra  |  Clinical News

AbbVie reports HCV combo results

AbbVie Inc. (NYSE:ABBV) and partner Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) reported new data from studies of a three direct-acting-antiviral (3-DAA) regimen of ABT-450 plus ombitasvir ( ABT-267), dasabuvir ( ABT-333) and the booster Norvir ritonavir in...